Giredestrant fails, but the group hopes for better luck in earlier therapy lines.
Targeting Shp2 has disappointed, but Novartis shows that it might still make an impression in directly hitting Kras.
An academic-sponsored trial gives Affimed’s NK cell engaging approach a huge endorsement.
A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.